These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 16956903)

  • 21. Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid of humans: implication for a bactericidal effect.
    Kanellakopoulou K; Pagoulatou A; Stroumpoulis K; Vafiadou M; Kranidioti H; Giamarellou H; Giamarellos-Bourboulis EJ
    J Antimicrob Chemother; 2008 Jun; 61(6):1328-31. PubMed ID: 18353805
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic-pharmacodynamic integration of moxifloxacin in rabbits after intravenous, intramuscular and oral administration.
    Fernández-Varón E; Bovaira MJ; Espuny A; Escudero E; Vancraeynest D; Cárceles CM
    J Vet Pharmacol Ther; 2005 Aug; 28(4):343-8. PubMed ID: 16050813
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of 2 moxifloxacin regimens for preoperative prophylaxis: prospective randomized triple-masked trial. Part 1: aqueous concentration of moxifloxacin.
    Vasavada AR; Gajjar D; Raj SM; Vasavada V; Vasavada V
    J Cataract Refract Surg; 2008 Aug; 34(8):1379-82. PubMed ID: 18655991
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum and prostatic tissue concentrations of moxifloxacin in patients undergoing transurethral resection of the prostate.
    Wagenlehner FM; Lunz JC; Kees F; Wieland W; Naber KG
    J Chemother; 2006 Oct; 18(5):485-9. PubMed ID: 17127224
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics and pharmacodynamics of three moxifloxacin dosage forms: implications for blinding in active-controlled cardiac repolarization studies.
    Mason JW; Florian JA; Garnett CE; Moon TE; Selness DS; Spaulding RR
    J Clin Pharmacol; 2010 Nov; 50(11):1249-59. PubMed ID: 20145260
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics and bioavailability of moxifloxacin in calves following different routes of administrations.
    Goudah A; Hasabelnaby S
    Chemotherapy; 2010; 56(1):26-31. PubMed ID: 20197659
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
    Odenholt I; Cars O
    J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Absolute bioavailability of moxifloxacin.
    Ballow C; Lettieri J; Agarwal V; Liu P; Stass H; Sullivan JT
    Clin Ther; 1999 Mar; 21(3):513-22. PubMed ID: 10321420
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diffusion of oral and intravenous 400 mg once-daily moxifloxacin into lung tissue at pharmacokinetic steady-state.
    Breilh D; Jougon J; Djabarouti S; Gordien JB; Xuereb F; Velly JF; Arvis P; Landreau V; Saux MC
    J Chemother; 2003 Dec; 15(6):558-62. PubMed ID: 14998080
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The penetration of moxifloxacin into the pancreas of male rats in experimental acute necrotizing pancreatitis.
    Wacke R; Park S; Mundkowski RG; Block N; Kuhn-Thiel A; Drewelow B
    Chemotherapy; 2003 Jul; 49(4):167-71. PubMed ID: 12886051
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics and milk penetration of moxifloxacin after intramuscular administration to lactating goats.
    Cárceles CM; Villamayor L; Escudero E; Marín P; Fernández-Varón E
    Vet J; 2007 Mar; 173(2):452-5. PubMed ID: 16377219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of activated charcoal on the pharmacokinetics of moxifloxacin following intravenous and oral administration of a 400 mg single dose to healthy males.
    Stass H; Kubitza D; Möller JG; Delesen H
    Br J Clin Pharmacol; 2005 May; 59(5):536-41. PubMed ID: 15842551
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential aqueous and vitreous concentrations of moxifloxacin and ofloxacin after topical administration one hour before vitrectomy.
    Lai WW; Chu KO; Chan KP; Choy KW; Wang CC; Tsang CW; Pang CP
    Am J Ophthalmol; 2007 Aug; 144(2):315-8. PubMed ID: 17659971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Penetration and accumulation of moxifloxacin in uterine tissue.
    Stass H; Kubitza D; Aydeniz B; Wallwiener D; Halabi A; Gleiter C
    Int J Gynaecol Obstet; 2008 Aug; 102(2):132-6. PubMed ID: 18501909
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Conjunctival tissue pharmacokinetic properties of topical azithromycin 1% and moxifloxacin 0.5% ophthalmic solutions: a single-dose, randomized, open-label, active-controlled trial in healthy adult volunteers.
    Torkildsen G; O'Brien TP
    Clin Ther; 2008 Nov; 30(11):2005-14. PubMed ID: 19108788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human intraocular penetration pharmacokinetics of moxifloxacin 0.5% via topical and collagen shield routes of administration.
    Hariprasad SM; Mieler WE; Shah GK; Blinder KJ; Apte RS; Holekamp NM; Thomas MA; Chi J; Prince RA
    Trans Am Ophthalmol Soc; 2004; 102():149-55; discussion 155-7. PubMed ID: 15747753
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sinus tissue concentration of moxifloxacin after a single oral dose.
    Dinis PB; Monteiro MC; Martins ML; Silva N; Morais JG
    Ann Otol Rhinol Laryngol; 2004 Feb; 113(2):142-6. PubMed ID: 14994771
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of intravenously administered moxifloxacin in eye compartments: an experimental study.
    Tzepi I; Vergados I; Kanellakopoulou K; Papathanassiou M; Kranidioti H; Tsaganos T; Liarakos V; Giamarellos-Bourboulis EJ; Theodossiadis P
    Int J Antimicrob Agents; 2009 Feb; 33(2):160-2. PubMed ID: 18947985
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concentration of moxifloxacin in serum and human aqueous humor following a single 400 mg oral dose.
    Walter S; Kuchenbecker J; Banditt P; Bode-Böger SM; Behrens-Baumann W
    J Cataract Refract Surg; 2007 Mar; 33(3):553-5. PubMed ID: 17321414
    [No Abstract]   [Full Text] [Related]  

  • 40. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
    Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W
    Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.